In the cervical carcinoma, Oh and co-workers [56] have determined the levels of EGFR in the serum of 38 patients (invasive or recurrent carcinoma (n = 26) and carcinoma in situ (CIS; n = 12)) and 38 healthy females as controls, using an enzyme-linked immunosorbent assay (ELISA). Here, EGFR is linked to in situ carcinoma.